| Bioactivity | Icotrokinra (JNJ-77242113) is a selective, orally active antagonist for IL-23 receptor. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. Icotrokinra exhibits anti-inflammatory activity in rat TNBS-induced colitis model[1]. |
| CAS | 2763602-16-8 |
| Sequence | Ac-Pen-Asn-Thr-Trp(7-Me)-Lys(Ac)-Pen-Phe(4-amino ethoxy)-2Nal-ThpGly-Glu-Asn-3Pal-Sar-NH2 (Pen1&Pen6 bridge) |
| Formula | C90H120N20O22S2 |
| Molar Mass | 1898.17 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14(1):17515. |
Icotrokinra
CAS: 2763602-16-8 F: C90H120N20O22S2 W: 1898.17
Icotrokinra (JNJ-77242113) is a selective, orally active antagonist for IL-23 receptor. Icotrokinra exhibits high affini
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.